How many 8-K filings has Plus Therapeutics, Inc. filed?

Plus Therapeutics, Inc. (PSTV) has 31 8-K (Current Event Report) filings on record, spanning Mar 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Plus Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Plus Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Plus Therapeutics, Inc. (PSTV) — 8-K Filings

All 8-K filings from Plus Therapeutics, Inc.. Browse 31 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (31)

Plus Therapeutics Files 8-K: Officer Changes and Compensation Details — Apr 9, 2026 Risk: medium
On April 8, 2026, PLUS THERAPEUTICS, INC. filed an 8-K report detailing the departure of a director and the appointment of a new officer. The filing also includ
PLUS THERAPEUTICS Files 8-K — Apr 8, 2026 Risk: low
On April 8, 2026, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. No specific financi
PLUS THERAPEUTICS 8-K: Item 5.02 Event Reported — Mar 26, 2026
PLUS THERAPEUTICS, INC. filed an 8-K on March 26, 2026, reporting an event under Item 5.02, which typically relates to changes in directors or officers or their
Plus Therapeutics Relocates Principal Executive Offices — Nov 17, 2025 Risk: low
On November 17, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2710 Reed Road,
PLUS THERAPEUTICS Enters Material Definitive Agreement — Oct 21, 2025 Risk: medium
On October 16, 2025, PLUS THERAPEUTICS, INC. entered into a material definitive agreement. This agreement also created a direct financial obligation for the reg
Plus Therapeutics Relocates Principal Executive Offices — Aug 26, 2025 Risk: low
On August 26, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2710 Reed Road, S
Plus Therapeutics Files 8-K Report — Aug 14, 2025 Risk: low
On August 14, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The compa
Plus Therapeutics Relocates Principal Executive Offices — Aug 13, 2025 Risk: low
On August 13, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Austin, TX to H
PLUS THERAPEUTICS Files 8-K on Security Holder Vote Matters — Aug 12, 2025 Risk: low
On August 7, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as C
PLUS THERAPEUTICS FILES 8-K: Accountant Change & Financials — Jul 18, 2025 Risk: low
On July 16, 2025, PLUS THERAPEUTICS, INC. (formerly CYTORI THERAPEUTICS, INC. and MACROPORE INC) filed an 8-K report. The filing indicates a change in the regis
PLUS THERAPEUTICS, INC. Files 8-K with Material Agreement — Jun 20, 2025 Risk: medium
On June 17, 2025, PLUS THERAPEUTICS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
PLUS THERAPEUTICS, INC. Files Material Definitive Agreement — Jun 17, 2025 Risk: medium
On June 17, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report detailing a material definitive agreement. The company, formerly known as CYTORI THERAPEUTICS, INC
Plus Therapeutics Faces Delisting Concerns — Jun 6, 2025 Risk: high
Plus Therapeutics, Inc. filed an 8-K on June 6, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company's
PLUS THERAPEUTICS, INC. Faces Delisting Concerns — May 23, 2025 Risk: high
On May 21, 2025, PLUS THERAPEUTICS, INC. filed an 8-K to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly know
Plus Therapeutics Faces Delisting Concerns — May 19, 2025 Risk: high
Plus Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting a notice of delisting or failure to meet continued listing standards as of May 16, 2025. The com
Plus Therapeutics Files 8-K with Corporate Updates — May 2, 2025 Risk: low
On May 2, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report detailing several corporate events. These include amendments to its articles of incorporation or byl
Plus Therapeutics Files 8-K: Board & Compensation Changes — Apr 18, 2025 Risk: medium
On April 18, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the
Plus Therapeutics Relocates Principal Executive Offices — Mar 27, 2025 Risk: low
On March 27, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Austin, Texas to
PLUS THERAPEUTICS, INC. Files 8-K — Mar 10, 2025 Risk: low
On March 7, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company's principal ex
PLUS THERAPEUTICS FILES 8-K: AGREEMENT & EQUITY SALES — Mar 4, 2025 Risk: medium
On March 4, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The company
PLUS THERAPEUTICS Files 8-K: Material Agreement, Financial Obligations — Feb 18, 2025 Risk: medium
On February 13, 2025, PLUS THERAPEUTICS, INC. entered into a material definitive agreement. The company also incurred a direct financial obligation and engaged
Plus Therapeutics Files 8-K, Updates Corporate Information — Nov 14, 2024 Risk: low
On November 14, 2024, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4200 Marathon B
Plus Therapeutics Relocates Principal Executive Offices — Nov 1, 2024 Risk: low
On October 30, 2024, PLUS THERAPEUTICS, INC. (formerly CYTORI THERAPEUTICS, INC. and MACROPORE INC) filed an 8-K report. The filing indicates a change in the co
Plus Therapeutics Faces Nasdaq Delisting Warning — Sep 6, 2024 Risk: high
Plus Therapeutics, Inc. announced on September 5, 2024, that it received a deficiency letter from the Nasdaq Stock Market indicating non-compliance with listing
PLUS THERAPEUTICS Files 8-K on Security Holder Vote — Aug 15, 2024 Risk: low
On August 15, 2024, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders.
Plus Therapeutics Appoints New Directors, Updates Executive Contracts — Jun 7, 2024 Risk: medium
On June 5, 2024, PLUS THERAPEUTICS, INC. announced changes in its board of directors and executive compensation. Specifically, the company elected two new direc
Plus Therapeutics Enters New Agreement, Terminates Old One — Jun 4, 2024 Risk: medium
On May 31, 2024, PLUS THERAPEUTICS, INC. entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. This
PLUS THERAPEUTICS Files 8-K on Shareholder Nominations — May 20, 2024 Risk: medium
On May 16, 2024, PLUS THERAPEUTICS, INC. filed an 8-K report detailing shareholder nominations for its upcoming annual meeting. The company, formerly known as C
PLUS THERAPEUTICS FILES 8-K WITH MATERIAL AGREEMENT — May 9, 2024 Risk: medium
On May 5, 2024, PLUS THERAPEUTICS, INC. entered into a material definitive agreement, potentially related to unregistered sales of equity securities. The filing
Plus Therapeutics Faces Delisting Concerns — Mar 14, 2024 Risk: high
Plus Therapeutics, Inc. filed an 8-K on March 14, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company'
Plus Therapeutics Files 8-K — Mar 13, 2024 Risk: low
On March 12, 2024, PLUS THERAPEUTICS, INC. (formerly CYTORI THERAPEUTICS, INC. and MACROPORE INC) filed an 8-K report. The filing primarily concerns Regulation

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX